ArticleJournal of enzyme inhibition and medicinal chemistry2022
Design, synthesis and molecular docking of new fused 1
Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 62 citations in OpenAlex.
- Discovery ofRSC advances · 2026Article
- Antiviral activity and chemical characterization of Egyptian Ziziphus spina-christi against human respiratory viruses.Scientific reports · 2026Article
- Article
- Recent advances in synthesis and medicinal chemistry of pyrrolodiazepines.Frontiers in chemistry · 2026Review
- Recent Developments in Heterocyclic Derivatives as Novel Cancer Therapeutics: From 2020-2024.Mini reviews in medicinal chemistry · 2026Review
- A Comprehensive Overview of the Therapeutic Potential of Pyrimidine Analogues in the Management of Colorectal Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Exploring the Anticancer Potential ofCurrent medicinal chemistry · 2026Article
- Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015-2025).RSC advances · 2025Review
- Development of a Novel Drug Delivery System "Nanoemulfoam" for Topical Delivery of Terbinafine Hydrochloride as a Repurposed Therapy in Skin Cancer: Formulation, Optimization, In Vitro Characterization, Ex Vivo Transdermal Permeability, Cytotoxicity Studies, and In Silico Assessment.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Targeted synthesis of a trimethoxyphenyltetrahydropyrimidine analogue designed as a DNA intercalator:RSC advances · 2025Article
- Unravelling Convergent Signaling Mechanisms Underlying the Aging-Disease Nexus Using Computational Language Analysis.Current issues in molecular biology · 2025Article
- Discovery of Novel Pyrimidine Based Small Molecule Inhibitors as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-cancer Studies.Current computer-aided drug design · 2025Article
- Advances in Small-molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-cancer Agents.Current medicinal chemistry · 2025Review
- Novel Small Molecule Inhibitors of Cyclin-dependent Kinases as Anticancer Agents.Current medicinal chemistry · 2025Review
- Biological evaluation, docking studies, andJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Pyrrolizine/indolizine-bearing (un)substituted isoindole moiety: design, synthesis, antiproliferative and MDR reversal activities, andRSC advances · 2023Article
- Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors.RSC advances · 2023Article
- Identification of new theobromine-based derivatives as potent VEGFR-2 inhibitors: design, semi-synthesis, biological evaluation, andRSC advances · 2023Article
- Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies of new thieno[2,3-RSC advances · 2023Article
- Discovery of new 5-substituted-indole-2-carboxamides as dual epidermal growth factor receptor (EGFR)/cyclin dependent kinase-2 (CDK2) inhibitors with potent antiproliferative action.RSC medicinal chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new series of 1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.